Evaluation of the Diagnostic Efficacy of Magnetic Resonance Imaging in Neurodegenerative Diseases: A Systematic Review of the Literature
Downloads
Introduction
Neurodegenerative diseases, such as Alzheimer's and Parkinson's, present complex clinical challenges due to the difficulty in achieving an accurate early diagnosis. Magnetic resonance imaging (MRI) has proven useful in identifying brain changes before clinical symptoms appear. However, its diagnostic efficacy compared to other methods, such as positron emission tomography (PET), remains under debate.
Objective
To evaluate the diagnostic accuracy of MRI in neurodegenerative diseases through a systematic review of the literature.
Methods
A systematic review of systematic reviews and meta-analyses evaluating the diagnostic accuracy of MRI in neurodegenerative diseases was conducted. Studies comparing MRI with other methods, such as CT or biomarkers, were included. Sensitivity, specificity, and ROC curves were assessed.
Results
Eight studies were included in the review. Structural MRI showed a sensitivity of 73% and a specificity of 71% for early detection of Alzheimer's in patients with mild cognitive impairment. In Parkinson's disease, functional MRI detected functional alterations with a significant reduction in the Amplitude of Low-Frequency Fluctuations in key motor areas. The combination of MRI with PET improved diagnostic accuracy, especially in the early diagnosis of Alzheimer's.
Discussion
The results highlight the potential of MRI for the early diagnosis of neurodegenerative diseases, although combining it with PET appears to offer greater diagnostic accuracy. Emerging techniques, such as MRI spectroscopy and elastography, could further improve early detection, though more studies are needed to standardize their use.
Fasano A, Laganiere SE, Lam S, Fox MD. Lesions causing freezing of gait localize to a cerebellar functional network. Ann Neurol. January 2017;81(1):129-41.
Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain J Neurol. December 2012;135(Pt 12):3749-56.
Lee J, Renslo J, Wong K, Clifford TG, Beutler BD, Kim PE, et al. Current Trends and Applications of PET/MRI Hybrid Imaging in Neurodegenerative Diseases and Normal Aging. Diagn Basel Switz. March 10, 2024;14(6):585.
Querbes O, Aubry F, Pariente J, Lotterie JA, Démonet JF, Duret V, et al. Early diagnosis of Alzheimer’s disease using cortical thickness: impact of cognitive reserve. Brain J Neurol. August 2009;132(Pt 8):2036-47.
Diogo VS, Ferreira HA, Prata D, for the Alzheimer’s Disease Neuroimaging Initiative. Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach. Alzheimers Res Ther. August 3, 2022;14(1):107.
Song T, Song X, Zhu C, Patrick R, Skurla M, Santangelo I, et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res Rev. December 2021;72:101503.
Lombardi G, Crescioli G, Cavedo E, Lucenteforte E, Casazza G, Bellatorre AG, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer’s disease in people with mild cognitive impairment. Cochrane Database Syst Rev. March 2, 2020;3(3)
Gu L, Shu H, Xu H, Wang Y. Functional brain changes in Parkinson’s disease: a whole brain ALE study. Neurol Sci. 2022. Available at: https://www.embase.com/search/results?subaction=viewrecord&id=L2018275844&from=export
Mohammadi S, Ghaderi S, Mohammadi H, Fatehi F. Simultaneous Increase of Mean Susceptibility and Mean Kurtosis in the Substantia Nigra as an MRI Neuroimaging Biomarker for Early-Stage Parkinson’s Disease: A Systematic Review and Meta-Analysis. J Magn Reson Imaging. 2024. Available at:
https://www.embase.com/search/results?subaction=viewrecord&id=L2031152388&from=export
Feng Y, Murphy MC, Hojo E, Li F, Roberts N. Magnetic Resonance Elastography in the Study of Neurodegenerative Diseases. J Magn Reson Imaging. January 2024;59(1):82-96.
Ruan Q, D’Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer’s disease: a systematic review. BMC Geriatr. May 16, 2016;16:104.
Carvalho BB, Döering TP, Ronchetti MR, Martins WA, Palmini AL. Neuroimagem no entendimento da evolução da doença de Alzheimer: da fase pré-sintomática à doença avançada. Acta Méd Porto Alegre. 2015;36:[7]-[7].
Li KR, Wu AG, Tang Y, He XP, Yu CL, Wu JM, et al. The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review. Mol Neurobiol. October 1, 2022;59(10):5935-54.
Stoessl AJ. Neuroimaging in the early diagnosis of neurodegenerative disease. Transl Neurodegener. January 13, 2012;1(1):5.
Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther. April 27, 2020;12(1):49.
Kamagata K, Andica C, Kato A, Saito Y, Uchida W, Hatano T, et al. Diffusion Magnetic Resonance Imaging-Based Biomarkers for Neurodegenerative Diseases. Int J Mol Sci. January 2021;22(10):5216.
Copyright (c) 2025 Gloria Ibis Tirado-Romero, Yamir Zuñiga Daza, Angelica Maria Marriaga Mendoza , Juan Sebastian Tirado Romero, Juan Alzate
This work is licensed under a Creative Commons Attribution 4.0 International License.
All Content should be original and unpublished.
